NetworkNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT
Post# of 151
(Total Views: 151)
Posted On: 03/24/2023 5:10:18 PM
NetworkNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Poised to Enable Expedited Care for Heart Attack Patients
HeartBeam (NASDAQ: BEAT) is developing the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere. “By applying a suite of proprietary algorithms to simplify vector electrocardiography (‘VECG’), the HeartBeam platform will enable patients and their clinicians to determine quickly and easily if symptoms are due to a heart attack so care can be expedited if required. HeartBeam has two patented products in development. HeartBeam AIMI(TM) is software for acute care settings that provides a 3D comparison of baseline and symptomatic 12-lead ECG to identify a heart attack more accurately. HeartBeam AIMIGo(TM) is the first and only credit-card-sized, 12-lead output ECG device coupled with a smartphone app and cloud-based diagnostic software system to facilitate remote heart-attack detection,” a recent article explains. “At HeartBeam, we are addressing the need to determine if someone who is experiencing signs of a heart attack at home, work or any place outside of a medical setting is actually experiencing one,” HeartBeam CEO and Founder Branislav Vajdic, PhD, is quoted as saying. “It’s a huge issue. On average, most people wait over three hours before seeking care… That time means that the mortality rate goes up by some 40%.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
HeartBeam (NASDAQ: BEAT) is developing the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere. “By applying a suite of proprietary algorithms to simplify vector electrocardiography (‘VECG’), the HeartBeam platform will enable patients and their clinicians to determine quickly and easily if symptoms are due to a heart attack so care can be expedited if required. HeartBeam has two patented products in development. HeartBeam AIMI(TM) is software for acute care settings that provides a 3D comparison of baseline and symptomatic 12-lead ECG to identify a heart attack more accurately. HeartBeam AIMIGo(TM) is the first and only credit-card-sized, 12-lead output ECG device coupled with a smartphone app and cloud-based diagnostic software system to facilitate remote heart-attack detection,” a recent article explains. “At HeartBeam, we are addressing the need to determine if someone who is experiencing signs of a heart attack at home, work or any place outside of a medical setting is actually experiencing one,” HeartBeam CEO and Founder Branislav Vajdic, PhD, is quoted as saying. “It’s a huge issue. On average, most people wait over three hours before seeking care… That time means that the mortality rate goes up by some 40%.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Heartbeam Inc. (BEAT) Stock Research Links
Scroll down for more posts ▼